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When aequorin-loaded platelets were stimulated with thrombin, the luminescence signal of aequorin showed 
two peaks. From experiments with 1 mM external Ca*+ or EGTA, both one-half of the first peak and the 
entire second peak reflected the influx of Ca 2+ from the external medium, and the remaining half of the 
first peak reflected the mobilization of Ca 2+ from its storage site. A monoclonal antibody (TM83) that re- 
cognizes the glycoprotein IIb/IIIa (GPIIb/IIIa) complex which has binding sites for fibrinogen and the syn- 
thetic peptide GRGDSP are known to inhibit fibrinogen binding and platelet aggregation. Both eliminated 
the second peak of intracellular free calcium ([Ca2+]i). Similar effects were observed during activation by 
collagen, but not during PMA activation. It was concluded that the GPIIb/IIIa complex was intimately 
related to a part of the Ca 2+ influx during the activation of platelets. 
Glycoprotein GPIIb/IIIa; intracellular free Ca 2+; Thrombin; Collagen; Platelet 
1. INTRODUCTION 
An increase in intracellular free Ca2+ level, 
[Ca2+]i, is an important process in platelet activa- 
tion. This increase in [Ca’+]i might be caused by 
mobilization from internal Ca2+-storage sites 
and/or influx from the extracellular medium. 
Recently, inositol 1,4,5trisphosphate, a hydrolytic 
product from phosphatidylinositol 1 ,Cbisphos- 
phate, has been suggested to act as a second 
messenger for the release of Ca2+ from intra- 
cellular storage sites [l]. The released Ca2+ return- 
ed by a Ca2+-pumping system to internal 
compartments for storage [2-41. On the other 
hand, the mechanism of Ca2+ flux across the 
platelet plasma membrane remains to be fully 
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clarified; Doyle and Ruegg [5] suggested that the 
platelet plasma membrane lacks Ca2+ channels. 
Furthermore, several investigators have failed to 
find Ca2+-ATPase in platelet plasma membranes 
12~41. 
Platelet membrane GPIIb and GPIIIa form a 
calcium-dependent heterodimer complex that con- 
tains binding sites for fibrinogen [6-91. It is also 
thought to be a Ca2+ -transport system across 
platelet plasma membranes in resting platelets [lo]. 
To clarify the role of GPIIb/IIIa in Ca2+ influx in 
human platelets under physiological conditions in 
a stirred medium, we employed aequorin as a 
[Ca2+]i indicator. Aequorin, which is a photopro- 
tein of molecular mass 20 kDa, binds Ca2+ and 
emits blue light [11,12], and the light emission of 
aequorin is not quenched by platelet aggregation. 
Here, we examined the effects of TM83 and a syn- 
thetic peptide, GRGDSP, on [Ca’+]i changes in 
stimulated platelets and analyzed the role of 
GPIIb/IIIa complex in these changes. 
228 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/87/$3.50 0 1987 Federation of European Biochemical Societies 
Volume 225, number 1,2 FEBS LETTERS December 1987 
2. MATERIALS AND METHODS 
Washed human platelets were prepared and then 
loaded with aequorin by using DMSO as in [13]. 
The aequorin-loaded platelets were suspended to 
about 3 x lo5 platelets/PI in Hepes-buffered saline 
(140 mM NaCl, 2.7 mM KCl, 1 mM MgC12, 
5.6 mM dextrose, 0.1% bovine albumin, 3.8 mM 
Hepes, pH 7.5). The platelet suspension was prein- 
cubated with 1 mM CaC12 for 5 min or 1 mM 
EGTA for 30 s in some experiments, and then in- 
cubated with TM83 (20 pg/ml) [15], mouse IgG 
(20pg/ml) or GRGDSP (100yM) [16,17] at 37°C 
for 3 min. Aggregation was initiated by the addi- 
tion of thrombin (final concentration, 0.05 or 
0.1 U/ml), collagen (5 pg/ml) or PMA (32 nM) to 
the platelet suspension in a platelet ionized calcium 
aggregometer (PICA, Chrono-Log, PA) with con- 
tinuous stirring. The increase in [Ca2+]i was 
calculated according to Johnson et al. [14]. 
Aequorin was purchased from Chrono-Log, cy- 
thrombin and phorbol 12-myristate 13-acetate 
(PMA) from Sigma, collagen from Hormon- 
Chemie, mouse IgG from Cappel, and the 
synthetic peptide Gly-Arg-Gly-Asp-Ser-Pro 
(GRGDSP) from Peninsula. The anti-GPIIb/IIIa 
monoclonal antibody TM83 (subclass IgG) was 
prepared by hybridization. TM83 immunoprecip- 
itated both GPIIb and Illa from ‘251-surface la- 
beled platelets. Crossed immunoelectrophoresis of
platelets against anti-whole platelet antibody with 
12*1-TM83 in the intermediate gel revealed that 
TM83 radioactivity was incorporated into both 
GPIIIa and the GPIIb/IIIa complex [15]. TM83 
was purified from mouse ascitic fluid by protein A- 
Sepharose chromatography. 
3. RESULTS 
As shown in fig.la, an increase in luminescence 
was observed immediately after the addition of 
thrombin in the control experiment (IgG). There 
was a small peak or a shoulder following the first 
peak. Pretreatment of the platelets with TM83 
eliminated the second peak of [Ca2+]i and de- 
creased the height of the first. A similar inhibitory 
effect was obtained on pretreatment with 
GRGDSP (fig.ld). When EGTA was added in the 
suspension, the first peak decreased to about 50% 
of the control, and the second peak was abolished 
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Fig.1. Effects of TM83, GRGDSP and EGTA on 
luminescence signals induced by various agonists. 
Platelets were preincubated with IgG (20 gg/ml), TM83 
(20 gg/ml), GRGDSP (100 PM) or 0.9% NaCl (control) 
for 3 min or 1 mM EGTA for 30 s, and then various 
agonists were added. Arrows show the addition of 
agonists. (a) 0.1 U/ml thrombin, (b) 10 pg/ml collagen, 
(c) 32 nM PMA, (d) 0.05 U/ml thrombin. (v) First 
peak, (v) second peak. 
(fig. la). On the other hand, the increase in [Ca’+]i 
induced by collagen or PMA did not show such a 
pattern of two peaks (fig.lb,c); the addition of 
EGTA reduced the [Ca2+]i increase induced by col- 
lagen and PMA. TM83 reduced the increase in 
[Ca’+]i induced by collagen, but not that by PMA. 
Table 1 summarizes the effects of TM83 on the in- 
creases in [Ca’+]i and aggregation induced by 
thrombin, collagen and PMA. TM83 significantly 
inhibited platelet aggregation by these agonists. 
TM83 reduced the [Ca2+]i ncreases induced by 
thrombin and collagen to 80 and 60% of the con- 
trol, respectively, but not that by PMA. Fig.2 
shows the effects of TM83 on changes in [Ca2+]i 
accompanying aggregation induced by thrombin. 
Thrombin-stimulated platelet aggregation was 
gradually inhibited by increasing concentrations of 
TM83. lOrg/ml of TM83 reduced thrombin- 
induced platelet aggregation to only 60% of the 
control value, while it completely eliminated the 
second peak of [Ca’+]i increase. 
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Table 1 
Summary of the effects of TM83 on increases in [Ca’+]i and aggregation induced 
by various agonists 
Rmwnt -.-..D’--’ !gG on ,,oh~i \-- ,-P’ ----I TAM83 (20 ,&?I!! 
Thrombin A [Ca’+]i GM) 1.33 f 0.53 1.07 + 0.48 
(0.05 U/ml, n = 7) aggregation (070) 53 +- 3.1 19 + 7.0” 
Collagen A [Ca’+]i @M) 0.93 * 0.14 0.56 * 0.11 
(5 pg/ml, n = 8) aggregation (Yo) 42 rf: 7.7 14 + 3.9” 
PMA A [Ca’+]i (uM) 0.46 + 0.04 0.43 + 0.06 
(32 nM, n = 6) aggregation (070) 29 + 8.7 8 f 1.4 
a p < 0.05, significantly different from pretreatment with IgG 
A [Ca’+]i, difference between resting [Ca’+]; and the first peak of [Ca’+]i induced 
by various agonists; Agg., transmittance change 3 min after the addition of 
agonists. Values are means * SE 
To investigate whether aggregation itself in- 
creases [Ca*+]i in platelets, increases in [Ca*+]i of 
platelets induced by the above agonists were 
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thrombin- and PMA-induced increases in [Ca*+]i 
were 1.23 pM (n = 2) and 0.52 ,uM (n = 4), respec- 
tively, in stirred mixtures. Both increases were 
reduced to about 80% for the non-stirred states 
(fig.3). The second peak induced by thrombin or 
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Fig.2. Effects of TM83 concentration on luminescence 
by 0.05 U/ml signals and aggregation induced 
thrombin. The degree of aggregation was calculated 
from the percent transmittance change after 3 min. 
Arrows indicate additions of thrombin. (v) First peak, 
(v) second peak. 
Fig.3. Effects of stirring conditions on luminescence 
signals induced by various agonists. Platelets in the 
cuvette were stirred continuously in the PICA before 
addition of agonists, then stirring was stopped or 
continued. (a) 0.05 U/ml thrombin, (b) lO~g/ml 
collagen, (c) 32 nM PMA. (7) First peak, (v) second 
peak. 
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the first peak by collagen was lost in the non- 
stirred state. 
4. DISCUSSION 
Using the DMSO method [ 131, aequorin-loaded 
platelets exhibited two peaks or a shoulder pattern 
of [Ca’+]i after stimulation by thrombin. When the 
platelets were stimulated by collagen or PMA, the 
second peak was absent. The presence of a second 
peak was not reported by others using a different 
loading method such as that of Johnson et al. [ 141. 
TM83, a monoclonal antibody against GPIIIa that 
recognizes the GPIIb/IIIa complex, inhibited 
collagen-, ADP- or thrombin-induced aggregation 
and fibrinogen binding, but did not inhibit ATP 
secretion induced by thrombin [15]. GRGDSP, 
which is known to inhibit fibrinogen binding to 
ADP- or thrombin-stimulated platelets, was 
reported to inhibit platelet aggregation but not 
ATP secretion induced by thrombin [16,17]. In 
platelets, TM83 and GRGDSP reduced the first 
peak and eliminated the second peak of [Ca’+]i in- 
duced by thrombin (fig.1, table 1). These effects 
were specific to GPIIb/IIIa since a monoclonal an- 
tibody to GPIb (TM60) [18] did not eliminate the 
second peak of [Ca2+]i induced by thrombin (not 
shown). The second peak of [Ca’+]i induced by 
thrombin was eliminated in the absence of ag- 
gregation under the non-stirred state (fig.3), sug- 
gesting that aggregation itself might be the 
triggering factor for the development of the second 
peak. However, a low concentration of TM83 par- 
tially inhibited thrombin-induced aggregation, but 
completely abolished the second peak of [Ca’+]i 
(fig.2). This result indicates that the intact 
GPIIb/IIIa complex might be essential for the 
development of the second peak. Since the first 
peak, though reduced in height, still remained in 
the presence of 1 mM EGTA, it consists of the sum 
of Ca2+ mobilization and Ca2+ influx. Using 
quin2-loaded platelets, Powling and Hardisty [19] 
reported that anti-GPIIb/IIIa monoclonal an- 
tibodies reduced the [Ca’+]i increases stimulated 
by several agonists including ADP, PAF and 
sodium arachidonate. They postulated that the ef- 
fect might be due to steric hindrance of a Ca2+ 
channel closely adjacent to the GPIIb/IIIa com- 
plex, because Glanzmann’s thrombasthenic 
platelets showed normal [Ca’+]i responses to ADP 
stimulation. In contrast, we demonstrated that not 
only the monoclonal antibody TM83, but also the 
synthetic peptide GRGDSP had the same in- 
hibitory effect on [Ca’+]i responses to thrombin. 
Since GRGDSP binds to only the GPIIb/IIIa com- 
plex as does TM83, the former inhibitory effect 
cannot be explained by a mechanism involving 
steric hindrance because of its low molecular mass. 
The collagen-induced increase in [Ca2+]i was 
also mediated by GPIIb/IIIa. Moreover, aggrega- 
tion itself was necessary for a collagen-induced in- 
crease in [Ca2+]i, since the peak of [Ca’+]i was 
completely lost without stirring (fig.2). However, 
PMA activation, which directly activated protein 
kinase C [20], was not mediated through 
GPIIb/IIIa and aggregation. 
According to the results, the mechanisms of 
Ca2+ influx into platelets can be classified into 
GPIIb/IIIa-dependent and independent pathways. 
Moreover, the presence of aggregation markedly 
influenced the [Ca2+]i induced by thrombin and 
collagen. A possible role for the GPIIb/IIIa com- 
plex in Ca2+ influx can be postulated: the binding 
of fibrinogen to GPIIb/IIIa and/or the incorpora- 
tion of GPIIb/IIIa into the cytoskeleton in ag- 
gregating platelets [21,22] might serve to open a 
pathway for Ca2+ influx in thrombin- and 
collagen-induced activation. 
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